Assistant Professor of @UMNHOT @UMNCancer. Former BMT Fellow @MayoClinic. Thoughts are my own.
Joined August 2022
- Tweets90
- Following100
- Followers73
- Likes28
Christopher Graham retweeted
A major update from ASTCT! New consensus grading criteria refine CRS and ICANS assessments and address emerging toxicities following immune effector cell therapy, supporting standardized toxicity evaluation across clinical trials and practice. ow.ly/Wsig5103RX0
Christopher Graham retweeted
Excited to share our new @BloodPortfolio manuscript comparing CAR-T vs BsAb in R/R FL.
In addition to comparing survival, we also studied "time toxicity," or how much time patients spend physically interacting with the healthcare system. #lymsm 🧵
ashpublications.org/bloodadv…
Christopher Graham retweeted
ASH welcomes its newly elected Executive Committee members! 👏
Bringing extensive experience and a shared commitment to advancing hematology, these leaders will help guide the Society's work in the years ahead.
Read the full announcement: ow.ly/1TWf5100YrV
Christopher Graham retweeted
In vivo CAR T: no apheresis, no manufacturing wait, no LD chemo.
Investigational LB2501 (CD19/CD20, @LegendBiotech) FIH, EHA 2026: DL2 ORR 6/6, CR 5/6, CRS gr1-2, no ICANS.
US IND now cleared. But n=6, 2.3 mo f/u: durability is the whole game.
#lymsm #CARTcells
Our study found that patients with baseline coronary artery calcifications (even in those with no cardiac history) had higher NRM following PTCy-based Gvhd prophylaxis and reduced intensity conditioning.
Study found that coronary artery calcification identified during pretransplant evaluation predicted non-relapse mortality in patients receiving PTCy. Among elderly patients without known coronary artery disease, it was associated with inferior survival. ow.ly/p4rP50ZPM6U
1
34
Christopher Graham retweeted
Study found that coronary artery calcification identified during pretransplant evaluation predicted non-relapse mortality in patients receiving PTCy. Among elderly patients without known coronary artery disease, it was associated with inferior survival. ow.ly/p4rP50ZPM6U
Christopher Graham retweeted
The latest ASTCT Consensus Grading for Toxicities after Immune Effector Cell Therapy has been published in Transplantation and Cellular Therapy, providing a standardized framework for grading toxicities associated with immune effector cell therapies. ,The guidance maintains and clarifies grading for CRS and ICANS, introduces modified ICE (M-ICE) for children and patients with developmental delays, and addresses emerging toxicities including hematotoxicity, IEC-HS and non-ICANS neurotoxicities.
📖 Read the full guideline: ow.ly/59na50ZOqrR
@ASTCT_Journal
Dexrazoxane shows cardioprotective effects in pediatrics exposed to anthracycline with ongoing benefits over time.
Longitudinal Change in Cardiac Function After Doxorubicin and Dexrazoxane: A Report From Children's Oncology Group ALTE11C2. Co-authored by @ErinMMobley.
Read the full article. bit.ly/4zbfA0r
79
Azer-cel shows promising results in CAR-naive NHLs and CAR-exposed DLBCL, but will this allo-CAR overcome and become the first commercially available allogeneic CAR-T?. Stay tuned. #ASCO2026
#ASCO26 attendees: Join me today at 1:30 pm at E450a as we discuss our results of the phase 1b study using Azer-cel, an allogeneic CD19 CAR-T in R/R NHL and CLL, not previously exposed to CAR-T.
@TeamImugene @UMNCancer @UMNews #lymsm
2
259
Christopher Graham retweeted
CONGRESS | #ASH25 | PRESENTATION
Samer Srour presents preliminary data of a phase I trial evaluating Orca-Q with (n = 18) or without (n = 26) GvHD prophylaxis (tacrolimus) in patients receiving allo-HSCT with 8/8 HLA-matched donors. Removal of pharmacologic GvHD prophylaxis did not increase GvHD rates and may improve infection rates. At 12 months, cumulative incidence of Grade ≥3 #aGvHD was 8.4% in the prophylaxis cohort vs 5.6% in the without prophylaxis cohort; similarly, incidence of moderate–severe #cGvHD was 11.8% and 0%, respectively.
Follow our live feed for more updates: loom.ly/TJPbnGM
Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content; a full list of supporters can be found on our website.
#GvHD #GvHDsm #MedEd #MedicalCongress
@MDAndersonNews
ICYMI: See our article in today’s ASH News Daily highlighting Dr. Nancy Speck’s E Donnall Thomas Lecture and Prize on her groundbreaking research in CBF leukemia @ASH_hematology @JoselleCookMD #ASH25 @SupriyaGuptaMD
ashpublications.org/ashnewsd…
#ASHkudos to Dr. Sanni, one of our fellows at #UMN who presented his research on HgSC disease cardiopulmonary risks and outcomes in inpatient setting. #ASH25
The first time I came to ash in 2023, I always admired the people giving oral presentations. I also wondered if I would ever be one of them. Today that dream came true ❤️ #ASH2025
Christopher Graham retweeted
Excited to share our abstract on cardiotoxicities with CAR-T therapy at #ASH25
Stop by poster #6301 to say hi 👋
@ChrisGrahamMD @SupriyaGuptaMD
#ASHkudos to all my ASH News Daily co-writers. It had been a pleasure writing with all of you. #ASH25 @JoselleCookMD @majorajay @SupriyaGuptaMD @ZanwarSaurabh @EmperorBlackMD @CKBrierley @ASH_hematology
It’s been a lot of fun acting as @JoselleCookMD's deputy in bringing #ASH25 ASHNewsDaily to life! Great to finally meet the team IRL today 😍
@ZanwarSaurabh
@EmperorBlackMD
@majorajay
@ChrisGrahamMD
@supriyaguptaMD
@ASH_hematology
#ASHkudos to Dr. Nancy Speck, the E. Donnall Thomas Lecture Prize Recipient for her groundbreaking discovery of CBF-beta, RUNX1 hematopoeisis, and ongoing research in RUNX1-FPD. @ASH_hematology #ASH25
2
156
Christopher Graham retweeted
Very proud to see our ARES study, demonstrating for the 1st time the efficacy of a fecal microbiota product in severe acute GVHD, featured in #ASH25 Newsdaily. More than a decade of rigorous research has now translated into a truly remarkable milestone. @MaaT_Pharma
Christopher Graham retweeted
CONGRESS | #ASH25 | PRESENTATION
Amandeep Salhotra shares results of a phase I trial of allogeneic CD6-CAR Tregs in patients with steroid-dependent or steroid-refractory #cGvHD (N = 6), noting that they can be successfully manufactured and cryopreserved. CD6-CAR Tregs cell infusion was not associated with significant toxicity, including CRS, ICANS, or GvHD flare.
Follow our live feed for more updates: loom.ly/TJPbnGM
Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content; a full list of supporters can be found on our website.
#GvHD #GvHDsm #MedEd #MedicalCongress @cityofhope
Christopher Graham retweeted
ICYMI: My piece covering Prof. Chiara Bonini’s inspiring Ham-Wasserman lecture was featured in today’s #ASHNewsDaily
Prof. Bonini took us through a journey in gene editing, innovation and the rapidly evolving future of cancer immunotherapy. 🧬
Grab your copy today!
#ASH25
Christopher Graham retweeted
Check out this #ASH25 special interest session on clonal hematopoesis today.
To all the GoT fans out there, here is our take covering the session highlights in today’s ASH Daily news!
@EmperorBlackMD @JoselleCookMD @ASH_hematology @CKBrierley @majorajay @ChrisGrahamMD @SupriyaGuptaMD
ashpublications.org/ashnewsd…